Genotoxic Impurities – Strategies for Identification and Control

The control of genotoxic impurities is crucial for ensuring regulatory compliance. With the implementation of increasingly stringent regulations for impurity levels, it is more important than ever for drug manufacturers to employ effective strategies for identifying, analysing and controlling GIs in their products.

This exciting new course - led by Andrew Teasdale, AstraZeneca - will provide you with the latest updates on regulatory expectations, clarifying any grey areas to outline your responsibilities as the manufacturer. It will also advise on crucial aspects of risk assessments and safety testing.

Using a combination of theory and practical case studies, the course will allow delegates to develop the knowledge needed to overcome everyday problems and enhance performance, ensuring you are employing the most appropriate analytical strategies for your products.

• Clarifying current guidelines and requirements for reporting genotoxic impurities
• Learning about current methods for assessing the risk posed by genotoxic impurities
• Exploring crucial strategies for safety testing
• Reviewing strategies for genotoxic impurity analysis
• Practical advice for overcoming everyday problems through the use of case studies and practical exercises